This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
TEM Q2 Revenues Soar Amid Coverage Issues: Time to Buy, Hold or Sell?
by Sridatri Sarkar
Tempus AI posts 89.6% Q2 revenue growth, raises 2025 sales outlook again, and sees positive adjusted EBITDA ahead. What is the investment outlook?
Zacks.com featured highlights include Tsakos Energy Navigation Limited, 10x Genomics, Pan American Silver, Wolverine World Wide and Interface
by Zacks Equity Research
Tsakos Energy Navigation, 10x Genomics, Pan American Silver, Wolverine World Wide, and Interface rank high on efficiency metrics, signaling strong profit potential in volatile markets.
5 Must-Buy Efficient Stocks to Buy Amid Volatile Market Conditions
by Santanu Roy
Tsakos Energy Navigation, 10x Genomics, Pan American Silver, Wolverine World Wide, and Interface top an efficiency-driven stock screen.
10x Genomics (TXG) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
10x Genomics (TXG) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
10x Genomics (TXG) delivered earnings and revenue surprises of +180.00% and +24.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
10x Genomics (TXG) Upgraded to Buy: Here's Why
by Zacks Equity Research
10x Genomics (TXG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Tempus AI Stock Before Q2 Earnings Release: To Buy or Not to Buy?
by Urmimala Biswas
TEM surged 34.5% in Q2 on AI-driven deals and product momentum, but valuation and profit concerns linger ahead of earnings.
3 Medical Info Systems Stocks to Buy Amid AI Boom and Tariff Risk
by Urmimala Biswas
AI momentum and rising demand for digital care put Zacks Medical Info Systems industry stocks like VEEV, TXG and IMDX in focus despite new tariff headwinds.
Wall Street Analysts Think 10x Genomics (TXG) Could Surge 43.12%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 43.1% in 10x Genomics (TXG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
10x Genomics (TXG) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
10x Genomics (TXG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Believe 10x Genomics (TXG) Could Rally 55.85%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 55.9% in 10x Genomics (TXG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Compared to Estimates, 10x Genomics (TXG) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
10x Genomics (TXG) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
10x Genomics (TXG) delivered earnings and revenue surprises of 20% and 16.24%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
10x Genomics (TXG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tempus AI Stock Surges 43% in Q1: Buy Now or Wait for Earnings?
by Urmimala Biswas
TEM's Genomics unit is expected to report strong growth for the first quarter, banking on continued unit growth pick-up.
Here's What Key Metrics Tell Us About 10x Genomics (TXG) Q4 Earnings
by Zacks Equity Research
The headline numbers for 10x Genomics (TXG) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
10x Genomics (TXG) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
10x Genomics (TXG) delivered earnings and revenue surprises of -25% and 0.03%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Seeking Clues to 10x Genomics (TXG) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for 10x Genomics (TXG), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
10x Genomics (TXG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tempus AI Stock Before Q4 Earnings: To Buy or Not to Buy?
by Urmimala Biswas
TEM's Genomics unit is expected to report strong growth for the fourth quarter, banking on continued unit growth pick-up.
10x Genomics (TXG) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for 10x Genomics (TXG) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
10x Genomics (TXG) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
10x Genomics (TXG) delivered earnings and revenue surprises of 11.76% and 0.02%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Medical Systems, 10x Genomics and Omnicell
by Zacks Equity Research
Medical Systems, 10x Genomics and Omnicell have been highlighted in this Industry Outlook article.
Lower Volume Likely to Hurt GE HealthCare's Q3 Earnings
by Zacks Equity Research
GEHC's third-quarter results are likely to witness declining segmental revenues in imaging, ultrasound and patient care. The bottom-line figure may reflect better pricing.
Lower Instruments Sales to Hurt TXG Q3 Earnings, Prelim Sales Down
by Zacks Equity Research
Per a preliminary report from 10x Genomics, the company's revenues will decline for the third quarter. Lower Instruments sales are likely to have been partially offset by consumable sales growth.